细胞衰老在肺癌微环境中的双向作用及其治疗意义

doi:10.3969/j.issn.1004-616x.2025.04.007

Abstract

CLC Number:

R734.2

ZHI Xiaochen, XIAO Ting. The bidirectional role of cellular senescence in the lung cancer microenvironment and its therapeutic significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 284-287.

References

[1] LI Y T, YAN B S, HE S M. Advances and challenges in the treatment of lung cancer[J]. Biomed Pharmacother, 2023, 169: 115891.
[2] LEE J H, SAXENA A, GIACCONE G. Advancements in small cell lung cancer[J]. Semin Cancer Biol, 2023, 93: 123-128.
[3] MANSOURI S, HEYLMANN D, STIEWE T, et al. Cancer genome and tumor microenvironment: reciprocal crosstalk shapes lung cancer plasticity[J]. eLife, 2022, 11: e79895.
[4] CAMPISI J. Cellular senescence and lung function during aging. Yin and Yang[J]. Annals ATS, 2016, 13(Sup 5): S402-S406.
[5] GORGOULIS V, ADAMS P D, ALIMONTI A, et al. Cellular senescence: defining a path forward[J]. Cell, 2019, 179(4): 813-827.
[6] SCHNEIDER J L, ROWE J H, GARCIA-DE-ALBA C, et al. The aging lung: Physiology, disease, and immunity[J]. Cell, 2021, 184(8): 1990-2019.
[7] DOMEN A, DEBEN C, VERSWYVEL J, et al. Cellular senescence in cancer: clinical detection and prognostic implications[J]. J Exp Clin Cancer Res, 2022, 41(1): 360.
[8] RUHLAND M K, ALSPACH E. Senescence and immunoregulation in the tumor microenvironment[J]. Front Cell Dev Biol, 2021, 9: 754069.
[9] TAKASUGI M, YOSHIDA Y, OHTANI N. Cellular senescence and the tumour microenvironment[J]. Mol Oncol, 2022, 16(18): 3333-3351.
[10] TCHKONIA T, ZHU Y, VAN DEURSEN J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities[J]. J Clin Invest, 2013, 123(3): 966-972.
[11] COPPé J P, DESPREZ P Y, KRTOLICA A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression[J]. Annu Rev Pathol Mech Dis, 2010, 5: 99-118.
[12] DEMARIA M, O’LEARY M N, CHANG J H, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse[J]. Cancer Discov, 2017, 7(2): 165-176.
[13] BATLLE E, MASSAGUé J. Transforming growth factor-β signaling in immunity and cancer[J]. Immunity, 2019, 50(4): 924-940.
[14] YANG X G, LIN Y L, SHI Y H, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling[J]. Cancer Res, 2016, 76(14): 4124-4135.
[15] COURAU T, NEHAR-BELAID D, FLOREZ L, et al. TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies[J]. JCI Insight, 2016, 1(9): e85974.
[16] FAGET D V, REN Q H, STEWART S A. Unmasking senescence: context-dependent effects of SASP in cancer[J]. Nat Rev Cancer, 2019, 19(8): 439-453.
[17] JHA S K, DE RUBIS G, DEVKOTA S R, et al. Cellular senescence in lung cancer: molecular mechanisms and therapeutic interventions[J]. Ageing Res Rev, 2024, 97: 102315.
[18] LOO T M, MIYATA K, TANAKA Y, et al. Cellular senescence and senescence-associated secretory phenotype via the cGAS-STING signaling pathway in cancer[J]. Cancer Sci, 2020, 111(2): 304-311.
[19] CRESPO J, SUN H Y, WELLING T H, et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment[J]. Curr Opin Immunol, 2013, 25(2): 214-221.
[20] ALSPACH E, LUSSIER D M, MICELI A P, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy[J]. Nature, 2019, 574(7780): 696-701.
[21] SADIGHI AKHA A A. Aging and the immune system: an overview[J]. J Immunol Methods, 2018, 463: 21-26.
[22] RU K, CUI L, WU C, et al. Exploring the molecular and immune landscape of cellular senescence in lung adenocarcinoma[J]. Front Immunol, 2024, 15: 1347770.
[23] SUMITOMO R, HIRAI T, FUJITA M, et al. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer[J]. Exp Ther Med, 2019, 18(6): 4490-4498.
[24] HASTON S, GONZALEZ-GUALDA E, MORSLI S, et al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer[J]. Cancer Cell, 2023, 41(7): 1242-1260.e6.
[25] RUHLAND M K, LOZA A J, CAPIETTO A H, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis[J]. Nat Commun, 2016, 7: 11762.
[26] SHIN E, BAK S H, PARK T, et al. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond[J]. Front Immunol, 2023, 14: 1192907.
[27] FORDER A, ZHUANG R, SOUZA V G P, et al. Mechanisms contributing to the comorbidity of COPD and lung cancer[J]. Int J Mol Sci, 2023, 24(3): 2859.
[28] BARNES P J, BAKER J, DONNELLY L E. Cellular senescence as a mechanism and target in chronic lung diseases[J]. Am J Respir Crit Care Med, 2019, 200(5): 556-564.
[29] HANSEL C, JENDROSSEK V, KLEIN D. Cellular senescence in the lung: the central role of senescent epithelial cells[J]. Int J Mol Sci, 2020, 21(9): 3279.
[30] ALTORKI N K, MARKOWITZ G J, GAO D C, et al. The lung microenvironment: an important regulator of tumour growth and metastasis[J]. Nat Rev Cancer, 2019, 19(1): 9-31.
[31] FANE M, WEERARATNA A T. How the ageing microenvironment influences tumour progression[J]. Nat Rev Cancer, 2020, 20(2): 89-106.
[32] LóPEZ-OTíN C, BLASCO M A, PARTRIDGE L, et al. Hallmarks of aging: an expanding universe[J]. Cell, 2023, 186(2): 243-278.
[33] BARTKOVA J, REZAEI N, LIONTOS M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints[J]. Nature, 2006, 444(7119): 633-637.
[34] TEDESCHI V, PALDINO G, KUNKL M, et al. CD8⁺ T cell senescence: lights and shadows in viral infections, autoimmune disorders and cancer[J]. Int J Mol Sci, 2022, 23(6): 3374.
[35] LEE S, SCHMITT C A. The dynamic nature of senescence in cancer[J]. Nat Cell Biol, 2019, 21(1): 94-101.
[36] CHILDS B G, DURIK M, BAKER D J, et al. Cellular senescence in aging and age-related disease: from mechanisms to therapy[J]. Nat Med, 2015, 21(12): 1424-1435.
[37] CHIBAYA L, SNYDER J, RUSCETTI M. Senescence and the tumor-immune landscape: implications for cancer immunotherapy[J]. Semin Cancer Biol, 2022, 86(Pt 3): 827-845.
[38] RUSCETTI M, LEIBOLD J, BOTT M J, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination[J]. Science, 2018, 362(6421): 1416-1422.
[39] KIRKLAND J L, TCHKONIA T. Senolytic drugs: from discovery to translation[J]. J Intern Med, 2020, 288(5): 518-536.
[40] ALEXA-STRATULAT T, PAVEL-TANASA M, CIANGA V A, et al. Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches[J]. Expert Rev Anticancer Ther, 2022, 22(11): 1197-1210.
[41] AMOR C, FEUCHT J, LEIBOLD J, et al. Senolytic CAR T cells reverse senescence-associated pathologies[J]. Nature, 2020, 583(7814): 127-132.
[42] MENG J S, LI Y, WAN C, et al. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis[J]. JCI Insight, 2021, 6(23): e146334.

The bidirectional role of cellular senescence in the lung cancer microenvironment and its therapeutic significance

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	JI Jie, MA Sheng, HUANG Guiwen, XIAO Ting. Expression and clinical significance of marker cofilin-1 in low-abundance proteome from plasma of lung adenocarcinoma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(3): 202-208.
[2]	XIE Peipei, ZHANG Qi, ZHANG Xiaoli, WAN Duo, ZHANG Wen, CHENG Shujun, ZHANG Kaitai. Development of a detection method for TERT positive white blood cells in patients with primary lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 431-437,443.
[3]	LIU Shiya, CHEN Meng, SHEN Gaigai, CAO Yuanting, SUN Lixin, RAN Yuliang. The combined effect and clinical value of cytoskeletal proteins MYH9 and Palladin in lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(5): 333-341.
[4]	ZHANG Xintong, GU Meng, WANG Ziyu, WEI Panjian, WANG Jinghui, TAN Jinjing. Control of blood glucose on targeted therapy in EGFR-mutated lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(5): 365-372,383.
[5]	. [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 315-319.
[6]	. [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 159-163.
[7]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[8]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[9]	QI Jiankao, TANG Xiao, SUN Shihui, KOU Yanfang, CUI Zhiqin. Growth inhibition of non-small cell lung cancers by Zaoci decotion in combination with cisplatin and gemcitabine [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 366-372,403.
[10]	FENG Zhiyin, WU Yixian, HA Xiaodan, CHEN Wujin, LI Xiumei, DONG Juanjuan. Detection of p38MAPK gene in plasma cell-free DNA among patients with high incidence of esophageal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 105-109.
[11]	WANG Rui, LIU Ying, WU Juan, JI Xiaokun, MA Yang, GUO Xiao, DU Yun. CXCR4, Ki67, MDM2 and N-cadherin expressions in lung adenocarcinoma pleural effusion cells and their correlation with EGFR mutation status [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 114-118.
[12]	WANG Rui, WANG Heng, WU Juan, JI Xiaokun, GUO Xiao, MA Yang, DU Yun. Values of automatic DNA image analyses in diagnosis of pancreatic malignant tumors [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 451-454.
[13]	ZENG Zhuoying, WU Desheng, LU Jingjing, LIAO Hui, LAI Hongpiao, YUAN Jianhui, HU Zhangli. Mediation by estrogen receptor α on oxidative phosphorylation pathways in development of lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 262-268.
[14]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[15]	WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192.